NLRP3 inflammasome‑driven satellite cell senescence orchestrates type‑1 fiber loss and ECM stiffening in presbyphonia

Hypothesis

Age‑related activation of the NLRP3 inflammasome in vocal fold satellite cells triggers a senescent secretory phenotype that preferentially depletes type 1 (slow‑twitch) thyroarytenoid fibers and drives fibroblast‑to‑myofibroblast conversion, resulting in collagen cross‑linking, elastin fragmentation, and hyaluronic acid loss.

Mechanistic Rationale

• Satellite cells in the lateral thyroarytenoid show reduced regenerative capacity with age [PMC3522788].
• Chronic low‑grade inflammation is a hallmark of aging muscle and can activate NLRP3, leading to IL‑1β and IL‑18 release.
• IL‑1β signaling suppresses MyoD expression, biasing satellite cells toward a non‑myogenic fate and promoting fibrosis via TGF‑β activation.
• Type 1 fibers are more oxidative and thus more susceptible to inflammasome‑induced ROS damage, explaining their preferential loss [10504602].
• Activated inflammasome signaling in fibroblasts upregulates α‑SMA and collagen‑I cross‑linking enzymes (LOX), stiffening the lamina propria [39709303].

Testable Predictions

1. We don't yet know if NLRP3 mRNA and protein levels will be higher in satellite cells isolated from >2‑year‑old rat lateral thyroarytenoid versus young controls, but we predict they will.
2. Pharmacological inhibition of NLRP3 (MCC950) will preserve type 1 fiber cross‑sectional area and reduce collagen‑I/III ratio in aged vocal folds.
3. Spatial transcriptomics will reveal a spatially restricted NLRP3‑high, MyoD‑low niche in the lateral compartment correlating with regions of fiber loss and ECM remodeling.
4. Conditioned media from NLRP3‑activated satellite cells will increase fibroblast α‑SMA expression and hyaluronidase‑2 activity in vitro.

Experimental Approach

• Obtain thyroarytenoid tissue from young (6 mo) and aged (24‑32 mo) rats; isolate satellite cells via Pax7‑FACS.
• Quantify NLRP3, ASC, caspase‑1 activity by Western blot and immunofluorescence; measure IL‑1β/IL‑18 by ELISA.
• Treat aged explants with MCC950 (10 µM) or vehicle for 7 days; assess fiber type composition (MyHC‑I vs MyHC‑II) and ECM composition (hydroxyproline, elastin, HA) via biochemical assays.
• Perform 10x Visium spatial transcriptomics on cryosections; map NLRP3, MyoD, TGFB1, COL1A1 expression patterns.
• In vitro co‑culture: satellite cells transfected with NLRP3‑siRNA or CRISPR‑KO; collect supernatant and apply to primary vocal fold fibroblasts; read out α‑SMA, LOX, HYAL2.

If predictions hold, the data would link a specific innate immune pathway to the dual muscle‑ECM degeneration seen in presbyphonia, offering a reparative target beyond symptomatic voice therapy.